Eterna Therapeutics Inc. has entered into a sponsored research agreement with a collaborator at The University of Texas MD Anderson Cancer Center (MD Anderson).
Modulation of a single amino acid in the reprogramming factor Kruppel-like factor 4 (KLF4) has been demonstrated to markedly improve natural transcription factor function and to result in faster and more effective reprogramming of somatic cells into induced pluripotent stem cells.
